AU1340101A - An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system - Google Patents

An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system

Info

Publication number
AU1340101A
AU1340101A AU13401/01A AU1340101A AU1340101A AU 1340101 A AU1340101 A AU 1340101A AU 13401/01 A AU13401/01 A AU 13401/01A AU 1340101 A AU1340101 A AU 1340101A AU 1340101 A AU1340101 A AU 1340101A
Authority
AU
Australia
Prior art keywords
immune system
effector functions
recombinant molecule
engineered recombinant
cellular effector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU13401/01A
Inventor
William L Fodor
Maryellen Pizzolato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of AU1340101A publication Critical patent/AU1340101A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU13401/01A 1999-10-22 2000-10-21 An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system Abandoned AU1340101A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16118699P 1999-10-22 1999-10-22
US60161186 1999-10-22
PCT/US2000/029151 WO2001030966A2 (en) 1999-10-22 2000-10-21 An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system

Publications (1)

Publication Number Publication Date
AU1340101A true AU1340101A (en) 2001-05-08

Family

ID=22580195

Family Applications (1)

Application Number Title Priority Date Filing Date
AU13401/01A Abandoned AU1340101A (en) 1999-10-22 2000-10-21 An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system

Country Status (4)

Country Link
EP (1) EP1165752A4 (en)
AU (1) AU1340101A (en)
CA (1) CA2361646A1 (en)
WO (1) WO2001030966A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ565711A (en) 2005-08-09 2011-10-28 Revivicor Inc Transgenic ungulates expressing a porcine CTLA4 peptide fused to an immunoglobulin
KR20180036810A (en) 2009-08-14 2018-04-09 레비비코르 인코포레이션 Multi-transgenic pigs for diabetes treatment
KR20130049775A (en) 2010-03-12 2013-05-14 애브비 바이오테라퓨틱스 인크. Ctla4 proteins and their uses
ES2680636T3 (en) 2011-02-14 2018-09-10 Revivicor Inc. Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof
CA3196707A1 (en) 2020-11-20 2022-05-27 Martine Rothblatt Multi-transgenic pigs with growth hormone receptor knockout for xenotransplantation
IL311538A (en) 2021-09-20 2024-05-01 Revivicor Inc Multitransgenic pigs comprising ten genetic modifications for xenotransplantation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US6090914A (en) * 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins

Also Published As

Publication number Publication date
EP1165752A4 (en) 2003-02-05
WO2001030966A3 (en) 2001-10-18
WO2001030966A2 (en) 2001-05-03
EP1165752A2 (en) 2002-01-02
CA2361646A1 (en) 2001-05-03

Similar Documents

Publication Publication Date Title
AU7602400A (en) Secreted proteins and uses thereof
IL223047A (en) Antibody comprising an fc region and uses thereof
AU6058500A (en) Fusion protein and uses thereof
EP1076090A2 (en) ESTs and encoded human proteins
EP1076090A3 (en) ESTs and encoded human proteins
AU7653500A (en) Method and system for finding the position of mobile terminals
AU1951201A (en) Peptide antigens
IL158751A0 (en) Recombinant fusion proteins and the trimers thereof
AU2002367859A1 (en) Polypeptide immobilization
AU2002365404A1 (en) Solid-phase immobilization of proteins and peptides
AU2001294834A1 (en) Recombinant bcg vaccines for the prevention and treatment of cancer
AU4776800A (en) Acetylcholinesterase-derived peptides and uses thereof
AU6394400A (en) Secreted proteins and uses thereof
AU1340101A (en) An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system
AU2002243314A1 (en) Immunogenic cancer peptides and uses thereof
AU7308200A (en) Novel hev antigenic peptide and methods
AU2002312373A1 (en) Structural and cytoskeleton-associated proteins
AU4759600A (en) Method and arrangement for enhancing the handling of tti identifier
GB9918155D0 (en) Proteins and peptides
AU5750200A (en) Secreted proteins and uses thereof
AU8168898A (en) Interferon stimulating protein and uses thereof
AU3382800A (en) Secreted proteins and uses thereof
AU3890200A (en) Novel porcine protein and uses thereof
AU2136401A (en) P450rai-2 and related proteins
AU5017700A (en) Secreted proteins and uses thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase